Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Loading history...
Latest & greatest articles for gestational diabetes
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on gestational diabetes or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on gestational diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com
WITHDRAWN: Dietary regulation for 'gestationaldiabetes'. Impaired glucose metabolism in pregnancy may be associated with adverse pregnancy outcomes. Primary dietary therapy is used in the management of diabetes, including gestational diabetes.The objective of this review was to assess the effects of primary dietary therapy in women identified as having gestationaldiabetes on fetal growth and neonatal outcomes.I searched the Cochrane Pregnancy and Childbirth Group trials register.Randomised
Efficacy and cost of postpartum screening strategies for diabetes among women with histories of gestationaldiabetes mellitus Efficacy and cost of postpartum screening strategies for diabetes among women with histories of gestationaldiabetes mellitus Efficacy and cost of postpartum screening strategies for diabetes among women with histories of gestationaldiabetes mellitus Kim C, Herman W H, Vijan S Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) . Type of economic evaluation Cost-effectiveness analysis Study objective To compare the cost and time to diagnosis associated with several screening strategies for diabetes in women with histories of gestationaldiabetes mellitus. Interventions The study compared different screening strategies after the 6-week postpartum oral glucose tolerance test (OGTT). The strategies included: a 2-hour 75-g OGTT annually, every 2 years or every 3 years; fasting plasma glucose (FPG) annually, every 2 years
Screening and active management reduced perinatal complications more than routine care in gestationaldiabetes Screening and active management reduced perinatal complications more than routine care in gestationaldiabetes | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Screening and active management reduced perinatal complications more than routine care in gestationaldiabetes Article Text Therapeutics Screening and active
Screening for gestationaldiabetes mellitus: a decision and cost-effectiveness analysis of four screening strategies Screening for gestationaldiabetes mellitus: a decision and cost-effectiveness analysis of four screening strategies Screening for gestationaldiabetes mellitus: a decision and cost-effectiveness analysis of four screening strategies Nicholson W K, Fleisher L A, Fox H E, Powe N R Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Three screening strategies for the detection of gestationaldiabetes mellitus (GDM) were examined: the sequential strategy, which consisted of an initial 50-g glucose challenge test followed, in those who test positive, by a 100-g glucose tolerance test (GTT); the 75-g GTT strategy
Effect of treatment of gestationaldiabetes mellitus on pregnancy outcomes. We conducted a randomized clinical trial to determine whether treatment of women with gestationaldiabetes mellitus reduced the risk of perinatal complications.We randomly assigned women between 24 and 34 weeks' gestation who had gestationaldiabetes to receive dietary advice, blood glucose monitoring, and insulin therapy as needed (the intervention group) or routine care. Primary outcomes included serious perinatal (...) to 1.62; P<0.001), although the rates of cesarean delivery were similar (31 percent and 32 percent, respectively; adjusted relative risk, 0.97; 95 percent confidence interval, 0.81 to 1.16; P=0.73). At three months post partum, data on the women's mood and quality of life, available for 573 women, revealed lower rates of depression and higher scores, consistent with improved health status, in the intervention group.Treatment of gestationaldiabetes reduces serious perinatal morbidity and may also
Effect of varying threshold and selective versus universal strategies on the cost in gestationaldiabetes mellitus Effect of varying threshold and selective versus universal strategies on the cost in gestationaldiabetes mellitus Effect of varying threshold and selective versus universal strategies on the cost in gestationaldiabetes mellitus Larijani B, Hossein-Nezhad A, Vassigh A R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS (...) EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The authors assessed the screening method best-suited for gestationaldiabetes mellitus (GDM) in Iran. The screening and diagnostic strategies compared were selective versus universal strategies with thresholds of 130 and 140 mg/dL. A two-step approach for screening and diagnosis was used
Treatments for gestationaldiabetes and impaired glucose tolerance in pregnancy. Gestationaldiabetes and impaired glucose tolerance (IGT) in pregnancy affects between 3 and 6% of all pregnancies and both have been associated with pregnancy complications. A lack of conclusive evidence has led clinicians to equate the risk of adverse perinatal outcome with pre-existing diabetes. Consequently, women are often intensively managed with increased obstetric monitoring, dietary regulation, and in some (...) cases insulin therapy. However, there has been no sound evidence base to support intensive treatment. The key issue for clinicians and consumers is whether treatment of gestationaldiabetes and IGT will improve perinatal outcome.The objective of this review was to compare alternative policies of care for women with gestationaldiabetes and IGT in pregnancy.We searched the Cochrane Pregnancy and Childbirth Group trials register (12 September 2002) and the bibliographies of relevant papers
Screening for gestationaldiabetes mellitus Screening for gestationaldiabetes mellitus Screening for gestationaldiabetes mellitus Brody S, Harris R P, Whitener B L, Krasnov C, Lux L J, Sutton S F, Lohr K N Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Brody S, Harris R P, Whitener B L, Krasnov C, Lux L J, Sutton S F, Lohr K N (...) . Screening for gestationaldiabetes mellitus. Rockville: Agency for Healthcare Research and Quality (AHRQ). Preventive Services Task Force Systematic Evidence Review No. 26. 2003 Authors' objectives To systematically review the evidence about the benefits and harms of screening pregnant women for gestationaldiabetes mellitus (GDM). Authors' conclusions The evidence of screening for GDM is insufficient to determine the extent to which screening has an important impact on maternal and neonatal health
Association of a woman's own birth weight with subsequent risk for gestationaldiabetes. Several studies have reported links between reduced fetal growth and subsequent risk for type 2 diabetes among older adults, but the association between indices of fetal growth and gestationaldiabetes mellitus (GDM), a major complication of pregnancy and a strong predictor of type 2 diabetes, remains little explored.To test the hypothesis that a woman's own fetal growth is inversely related to her later (...) and adjusted for gestational age.Birth weight showed a U-shaped relationship to a woman's risk of GDM in her first pregnancy, with the highest risks associated with low and high birth weights. Odds ratios (ORs) adjusted for gestational age were 2.16 (95% confidence interval [CI], 1.04-4.50) for birth weight of less than 2000 g and 1.53 (95% CI, 1.03-2.27) for a birth weight of 4000 g or more. Adjustment for potential confounding factors, particularly prepregnancy body mass index and maternal diabetes
Cost-effectiveness analysis of gestationaldiabetes mellitus screening in France Cost-effectiveness analysis of gestationaldiabetes mellitus screening in France Cost-effectiveness analysis of gestationaldiabetes mellitus screening in France Poncet B, Touzet S, Rocher L, Berland M, Orgiazzi J, Colin C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Three screening strategies for gestationaldiabetes mellitus were examined: strategy one (S1), screening of high-risk pregnant women with the 50 g oral glucose tolerance test (OGTT); strategy two (S2), screening of all pregnant women with the 50 g OGTT; and strategy 3 (S3), screening of all pregnant women with the 75 g OGTT. The 50 g OGTT requires confirmation by the 100 g
Screening for gestationaldiabetes: a systematic review and economic evaluation Screening for gestationaldiabetes: a systematic review and economic evaluation Screening for gestationaldiabetes: a systematic review and economic evaluation Scott D A, Loveman E, McIntyre L, Waugh N Authors' objectives To review research on screening for gestationaldiabetes mellitus (GDM). The review focused on the diagnostic performance and costs of various screening methods. The authors also assessed GDM (...) Scott D A, Loveman E, McIntyre L, Waugh N. Screening for gestationaldiabetes: a systematic review and economic evaluation. Health Technology Assessment 2002; 6(11): 1-172 PubMedID Original Paper URL Indexing Status Subject indexing assigned by NLM MeSH Adolescent; Adult; Age Distribution; Cost-Benefit Analysis; Diabetes, Gestational /diagnosis /epidemiology; Female; Great Britain /epidemiology; Humans; Incidence; Mass Screening /economics /methods; Maternal Age; Middle Aged; Pregnancy; Pregnancy
Screening for gestationaldiabetes: a systematic review and economic evaluation Screening for gestationaldiabetes: a systematic review and economic evaluation Screening for gestationaldiabetes: a systematic review and economic evaluation Scott D A, Loveman E, McIntyre L, Waugh N Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Scott D (...) A, Loveman E, McIntyre L, Waugh N. Screening for gestationaldiabetes: a systematic review and economic evaluation. Health Technology Assessment 2002; 6(11): 1-172 Authors' objectives The aim of this report is to provide an updated review of current knowledge, to clarify research needs, and to assist with policy making in the interim, pending future research. Authors' conclusions There are clearly some women whose glucose levels rise sufficiently in pregnancy to cause harm to their babies. However
Dietary regulation for 'gestationaldiabetes'. Impaired glucose metabolism in pregnancy may be associated with adverse pregnancy outcomes. Primary dietary therapy is used in the management of diabetes, including gestational diabetes.The objective of this review was to assess the effects of primary dietary therapy in women identified as having gestationaldiabetes on fetal growth and neonatal outcomes.I searched the Cochrane Pregnancy and Childbirth Group trials register.Randomised trials
A comparison of glyburide and insulin in women with gestationaldiabetes mellitus. Women with gestationaldiabetes mellitus are rarely treated with a sulfonylurea drug, because of concern about teratogenicity and neonatal hypoglycemia. There is little information about the efficacy of these drugs in this group of women.We studied 404 women with singleton pregnancies and gestationaldiabetes that required treatment. The women were randomly assigned between 11 and 33 weeks of gestation to receive (...) percent and 4 percent); who had lung complications (8 percent and 6 percent); who had hypoglycemia (9 percent and 6 percent); who were admitted to a neonatal intensive care unit (6 percent and 7 percent); or who had fetal anomalies (2 percent and 2 percent). The cord-serum insulin concentrations were similar in the two groups, and glyburide was not detected in the cord serum of any infant in the glyburide group.In women with gestationaldiabetes, glyburide is a clinically effective alternative
Managed care does not lower costs but may result in poorer outcomes for patients with gestationaldiabetes Managed care does not lower costs but may result in poorer outcomes for patients with gestationaldiabetes Managed care does not lower costs but may result in poorer outcomes for patients with gestationaldiabetes Bienstock J L, Blakemore K J, Wang E, Presser D, Misra D, Pressman E K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Management of gestationaldiabetes; Female genital diseases and pregnancy complications. Type of intervention Primary prevention and secondary prevention. Economic study type Cost-effectiveness analysis. Study population Patients with diagnosed gestationaldiabetes. Setting Primary care
Postprandial versus preprandial blood glucose monitoring in women with gestationaldiabetes mellitus requiring insulin therapy. The fetuses of women with gestationaldiabetes mellitus are at risk for macrosomia and its attendant complications. The best method of achieving euglycemia in these women and reducing morbidity in their infants is not known. We compared the efficacy of postprandial and preprandial monitoring in achieving glycemic control in women with gestational diabetes.We studied 66 (...) women with gestationaldiabetes mellitus who required insulin therapy at 30 weeks of gestation or earlier. The women were randomly assigned to have their diabetes managed according to the results of preprandial monitoring or postprandial monitoring (one hour after meals) of blood glucose concentrations. Both groups were also monitored with fasting blood glucose measurements. The goal of insulin therapy was a preprandial value of 60 to 105 mg per deciliter (3.3 to 5.9 mmol per liter